{"id":"W3130535105","doi":"10.1016/j.urology.2020.11.080","title":"A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or Enzalutamide","year":2021,"lang":"en","type":"article","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; University Health Network; University of Toronto","funders":"Ontario Ministry of Health and Long-Term Care; Institute for Clinical Evaluative Sciences; Astellas Pharma Canada; Princess Margaret Cancer Foundation; Merck; Janssen Pharmaceuticals; Bayer","keywords":"Medicine; Enzalutamide; Abiraterone acetate; Prostate cancer; Hazard ratio; Internal medicine; Population; Abiraterone; Retrospective cohort study; Cohort; Proportional hazards model; Medical record; Cancer; Oncology; Androgen deprivation therapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009381304,0.0005598619,0.0009232207,0.0008644468,0.0008038465,0.001288105,0.000627253,0.001284806,0.002000378],"category_scores_gemma":[0.003154163,0.0005264246,0.00201174,0.001639153,0.0005732947,0.0009450683,0.0007564556,0.00162892,0.0003153266],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009086065,"about_ca_system_score_gemma":0.0006538617,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01017481,"about_ca_topic_score_gemma":0.01020776,"domain_scores_codex":[0.9986745,0.0004812977,0.0001369816,0.0003574429,0.000161796,0.0001879431],"domain_scores_gemma":[0.9978807,0.0005836987,0.0007061363,0.0001499903,0.0002127567,0.0004666606],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.007873684,0.0007775514,0.9872547,0.00004857461,0.001728578,0.0001775643,0.0001977076,0.00009212796,0.0004262115,0.00003905037,0.000186845,0.001197384],"study_design_scores_gemma":[0.001176862,0.003652961,0.992336,0.00001363063,0.0009434987,0.0003605687,0.0007757756,0.0003117755,0.00006893797,0.00005990594,0.0002729779,0.00002707361],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9992317,0.0001845735,0.00003634295,0.00002966064,0.00001107642,0.00001490873,0.0002472865,0.00000181982,0.0002425898],"genre_scores_gemma":[0.9992505,0.00008381094,0.00003065824,0.00005338501,0.0000221484,0.00001599531,0.0004063129,0.00000195884,0.0001353069],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01017481,"threshold_uncertainty_score":0.02023119,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05308431478800026,"score_gpt":0.3638635605801991,"score_spread":0.3107792457921989,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}